The $45.6 billion unsolicited offer for Allergan by Valeant Pharmaceuticals and William A. Ackman’s hedge fund is a new twist in the war between companies and shareholder activists.
By STEVEN M. DAVIDOFF, NY Times: Business
Tue, 04/22/2014 - 10:31am
The $45.6 billion unsolicited offer for Allergan by Valeant Pharmaceuticals and William A. Ackman’s hedge fund is a new twist in the war between companies and shareholder activists.